Puma Biotechnology, Inc. announced that it has entered into note purchase agreement for an aggregate gross proceeds of $125 million on July 23, 2021. The transaction includes participation from new investor, Athyrium Capital Management, LP through its fund. The company will receive funding in two tranches. The notes will become due in July 2026. On the same date, the company received $100 million in its first tranche closing. The second tranche of $25 million may be received at a later date.